Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The disruption of protein−protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition
Michael A. Serwetnyk, Brian S. J. Blagg
Acta Pharmaceutica Sinica B (2020) Vol. 11, Iss. 6, pp. 1446-1468
Open Access | Times Cited: 65

Showing 1-25 of 65 citing articles:

An update on the status of HSP90 inhibitors in cancer clinical trials
Shraddha Rastogi, Abhinav Joshi, Nahoko Sato, et al.
Cell Stress and Chaperones (2024) Vol. 29, Iss. 4, pp. 519-539
Open Access | Times Cited: 21
Misfolding and aggregation in neurodegenerative diseases: protein quality control machinery as potential therapeutic clearance pathways
Oliwia Koszła, Przemysław Sołek
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 17
Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities
Jaka Dernovšek, Tihomir Tomašič
Pharmacology & Therapeutics (2023) Vol. 245, pp. 108396-108396
Open Access | Times Cited: 23
Small molecule inhibitors targeting heat shock protein 90: An updated review
Yulong Li, Jinyun Dong, Jiang‐Jiang Qin
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116562-116562
Closed Access | Times Cited: 8
Senescence-related gene c-Myc affects bladder cancer cell senescence by interacting with HSP90B1 to regulate cisplatin sensitivity
Yaxuan Wang, Haixia Zhu, Haifei Xu, et al.
Aging (2023)
Open Access | Times Cited: 17
New Class of Hsp90 C-Terminal Domain Inhibitors with Anti-tumor Properties against Triple-Negative Breast Cancer
Živa Zajec, Jaka Dernovšek, Jernej Cingl, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 15, pp. 12984-13018
Open Access | Times Cited: 7
Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress
Yajun Liu, Chenyao Li, Hongwei Liu, et al.
Archives of Pharmacal Research (2024) Vol. 47, Iss. 5, pp. 442-464
Closed Access | Times Cited: 6
Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects
Xinqi Liang, Ruixian Chen, Chengdi Wang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 18, pp. 15968-15995
Closed Access | Times Cited: 6
Recent advances toward the development of Hsp90 C-terminal inhibitors
Eva Amatya, Brian S. J. Blagg
Bioorganic & Medicinal Chemistry Letters (2022) Vol. 80, pp. 129111-129111
Open Access | Times Cited: 27
Targeted Protein Degradation Induced by HEMTACs Based on HSP90
Zhenzhen Li, Siyue Ma, Ling Zhang, et al.
Journal of Medicinal Chemistry (2022) Vol. 66, Iss. 1, pp. 733-751
Closed Access | Times Cited: 25
AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma
Chunyan Gu, Yajun Wang, Lulin Zhang, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 24
Heat Shock Protein 90 as Therapeutic Target for CVDs and Heart Ageing
Siarhei A. Dabravolski, Vasily N. Sukhorukov, Vladislav Kalmykov, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 649-649
Open Access | Times Cited: 24
Modulators of the Hop-HSP90 Protein-Protein Interaction Disrupt Early-Stage of KSHV Lytic Replication
Clinton G. L. Veale, Michael Okpara, Michaelone Vaaltyn, et al.
(2024)
Open Access | Times Cited: 5
Genetic and structural insights into the functional importance of the conserved gly-met-rich C-terminal tails in bacterial chaperonins
C. M. Santosh Kumar, Mohyuddin Aisha, Shekhar C. Mande, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
Cardiac fibrosis inhibitor CTPR390 prevents structural and morphological changes in collagen and fibroblasts of engineered human connective tissue
David Maestro, Ana Palanca, H. Soto, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Hsp90 and Associated Co-Chaperones of the Malaria Parasite
Tanima Dutta, Harpreet Singh, Adrienne L. Edkins, et al.
Biomolecules (2022) Vol. 12, Iss. 8, pp. 1018-1018
Open Access | Times Cited: 16
Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications
Mina Ardestani, Zahra Khorsandi, Fariba Keshavarzipour, et al.
Pharmaceutics (2022) Vol. 14, Iss. 10, pp. 2220-2220
Open Access | Times Cited: 16
The LINC00501-HSP90B1-STAT3 positive feedback loop promotes malignant behavior in gastric cancer cells
Miaomiao Pei, Nanzhu Xu, Jiaying Li, et al.
Cellular Signalling (2023) Vol. 108, pp. 110711-110711
Open Access | Times Cited: 9
HSP70 Is a Critical Regulator of HSP90 Inhibitor’s Effectiveness in Preventing HCl-Induced Chronic Lung Injury and Pulmonary Fibrosis
Ruben Manuel Luciano Colunga Biancatelli, Pavel Solopov, Tierney Day, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1920-1920
Open Access | Times Cited: 3
Discovery of new Hsp90–Cdc37 protein–protein interaction inhibitors: in silico screening and optimization of anticancer activity
Jaka Dernovšek, Nina Gradišek, Živa Zajec, et al.
RSC Advances (2024) Vol. 14, Iss. 39, pp. 28347-28375
Open Access | Times Cited: 3
Modulators of the Hop-HSP90 Protein–Protein Interaction Disrupt KSHV Lytic Replication
Michael Okpara, Michaelone Vaaltyn, Jessica L. Watson, et al.
ACS Infectious Diseases (2024) Vol. 10, Iss. 11, pp. 3853-3867
Open Access | Times Cited: 3
Structure, Function, and Inhibitors of the Mitochondrial Chaperone TRAP1
Soosung Kang, Byoung Heon Kang
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16155-16172
Closed Access | Times Cited: 14
Rational design, synthesis and structural characterization of peptides and peptidomimetics to target Hsp90/Cdc37 interaction for treating hepatocellular carcinoma
Surya Sukumaran, Mingdian Tan, Shulamit Fluss Ben-Uliel, et al.
Computational and Structural Biotechnology Journal (2023) Vol. 21, pp. 3159-3172
Open Access | Times Cited: 8
Discovery of novel Hsp90 C-terminal domain inhibitors that disrupt co-chaperone binding
Oi Wei Mak, Nabangshu Sharma, Jóhannes Reynisson, et al.
Bioorganic & Medicinal Chemistry Letters (2021) Vol. 38, pp. 127857-127857
Closed Access | Times Cited: 18
Ginsenoside Rg5 enhances the radiosensitivity of lung adenocarcinoma via reducing HSP90-CDC37 interaction and promoting client protein degradation
Hansong Bai, Jiahua Lyu, Xinyu Nie, et al.
Journal of Pharmaceutical Analysis (2023) Vol. 13, Iss. 11, pp. 1296-1308
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top